The neoepitope landscape of breast cancer: implications for immunotherapy
2019
Background
Cancer immunotherapy with immune checkpoint blockade (CKB) is now standard of care for multiple cancers. The clinical response to CKB is associated with T cell immunity targeting cancer-induced mutations that generate novel HLA-binding epitopes (neoepitopes).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
64
References
39
Citations
NaN
KQI